Insider Transactions in Q2 2024 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Octavio Espinoza Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
267
+1.12%
|
$16,020
$60.71 P/Share
|
|
Jun 28
2024
|
Matthew E Korenberg President & COO |
BUY
Other acquisition or disposition
|
Direct |
350
+0.4%
|
$21,000
$60.71 P/Share
|
|
Jun 28
2024
|
Andrew Reardon CLO & Secretary |
BUY
Other acquisition or disposition
|
Direct |
329
+1.44%
|
$19,740
$60.71 P/Share
|
|
Jun 28
2024
|
Todd C Davis Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
350
+0.29%
|
$21,000
$60.71 P/Share
|
|
Jun 14
2024
|
Stephen L Sabba Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,252
+3.98%
|
-
|
|
Jun 14
2024
|
Jason Aryeh Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,252
+1.58%
|
-
|
|
Jun 14
2024
|
Nancy Ryan Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,252
+15.39%
|
-
|
|
Jun 14
2024
|
Jason Haas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,252
+18.83%
|
-
|
|
Jun 14
2024
|
John W Kozarich Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,252
+2.78%
|
-
|
|
Jun 14
2024
|
John L Lamattina Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,252
+4.07%
|
-
|
|
Jun 14
2024
|
Martine Zimmermann Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,252
+26.14%
|
-
|
|
May 17
2024
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,156
-9.08%
|
$443,416
$86.66 P/Share
|
|
May 17
2024
|
Octavio Espinoza Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,917
+5.68%
|
$415,020
$60.61 P/Share
|
|
May 16
2024
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,264
-9.48%
|
$194,704
$86.0 P/Share
|
|
May 15
2024
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,873
-19.74%
|
$505,078
$86.01 P/Share
|
|
May 14
2024
|
Matthew E Korenberg President & COO |
SELL
Open market or private sale
|
Direct |
14,158
-7.09%
|
$1,203,430
$85.38 P/Share
|
|
May 13
2024
|
Matthew E Korenberg President & COO |
SELL
Open market or private sale
|
Direct |
3,440
-3.31%
|
$288,960
$84.54 P/Share
|
|
May 09
2024
|
Nancy Ryan Gray Director |
SELL
Open market or private sale
|
Direct |
934
-14.22%
|
$77,522
$83.2 P/Share
|
|
May 09
2024
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
10,000
-31.05%
|
$830,000
$83.04 P/Share
|
|
May 09
2024
|
Andrew Reardon CLO & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+23.69%
|
$520,000
$52.27 P/Share
|
|
Apr 30
2024
|
Jason Aryeh Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,406
+3.04%
|
$125,112
$52.3 P/Share
|
|
Apr 24
2024
|
John W Kozarich Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,893
+6.37%
|
$112,827
$39.35 P/Share
|